About:
Nexo Therapeutics is discovering and developing small molecule drugs for cancer patients. For many diseases the most compelling drug targets have been identified, but many still lack molecules that modulate the target. By being at the nexus of biology and chemistry, Nexo is is using two purpose-built platforms to mitigate this challenge: INFINI-T, a biology engine that yields details on the depth and duration of target modulation needed, and CODON, a ligand discovery engine to match small molecules to target biology. Nexo is collaborating with MD Anderson to enable translation of targets to clinical studies.